Polyneuropathies
33
8
9
11
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.1%
2 terminated out of 33 trials
84.6%
-1.9% vs benchmark
15%
5 trials in Phase 3/4
27%
3 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (33)
A Phase 3 Study of NTLA-2001 in ATTRv-PN
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
ChatGPT in the Diagnosis and Management of Complex Polyneuropathies: Comparative Analysis With Neurologists Using Real-World Cases
Effect of Exercise and Surgical Weight Loss on Polyneuropathy
Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
Individual Patient Expanded Access IND to Treat Polyneuropathy
Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
Diagnostic Feasibility of 100 Hz Tetanic Stimulation
Assessment of Effectiveness and Stimulation Coverage of Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy in Patients with Cervical Lead Placement
Ultrasonography in Diagnosis of Polyneuropathy
Prognostic Value of Biomarkers in Polyneuropathy.
Exploring the Genetics of Neuropathic Pain
Sensory Neuropathy Scores Validated by Quantitative Sensory Testing and Nerve Conduction Studies for Kidney Transplant Recipients
Polyneuropathy and COVID-19
Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer
Physical Activity in Persons With Charcot-Marie-Tooth: Developing a Measurement Instrument